The tweet was deleted by the author.
But we saved everything 🙂.
Biohaven is preparing to present data from its ongoing Phase 1 trial of an investigational FGFR3-directed ADC during a plenary session at ENA2026 in Barcelona. The stock is little changed on the day, trading near $13.8.
Biohaven is set to attend ENA2026 in Barcelona. The company will present new data from the ongoing Phase 1 trial of its investigational FGFR3-directed ADC in a plenary oral presentation. In addition, Biohaven will showcase its proprietary TopoIx ADC platform.
View post on X Loading...
Stoch RSI is in oversold territory, offering some support against further downside in shares of Biohaven. The price is currently positioned below the MA-20 but remains above the MA-50 and MA-200, reflecting a split daily chart structure. The nearest support sits at the Ichimoku Kijun at $13.6, helping to anchor short-term price action.
A move above $14.54 would indicate growing buyer interest and confirm that the event is being priced in, while a drop below $13.6 would suggest the move is being rejected. With Stoch RSI stretched in oversold territory, scope for additional losses is limited and may foster near-term stabilization. Even so, after a sharp move lower over the past week without a sustained trend, the probability for downside is 59% and upside is 41% over the next five trading days, with an expected trading range between $12.88 and $14.71. On the weekly chart the longer-term picture stays mixed.
Previously it was reported that Biohaven's outlook turned bullish following a collaboration deal, as technical indicators pointed to upside potential. With the stock now consolidating near support ahead of key trial data at ENA2026, the prevailing scenario suggests a mixed but potentially stabilizing range, with $13.6 emerging as a critical level to monitor for directional cues.